TLE1 as a key regulator of osimertinib resistance and EMT in lung adenocarcinoma: implications for prognosis and immunotherapy response
Na Chen, Tianlin Wang, Yi Li, Ruixia Zhang, Xiduan Wei, Zhenglu Wang · 2026
Read TLE1 as a key regulator of osimertinib resistance and EMT in lung adenocarcinoma: implications for prognosis and immunotherapy response by Na Chen, Tianlin Wang, Yi Li, Ruixia Zhang, Xiduan Wei, Zhenglu Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13425785.txt.
Description
Na Chen and colleagues hunt for a marker of resistance to osimertinib, a drug used for lung adenocarcinoma, a common form of non-small cell lung cancer. Long-term treatment often fails as tumours learn to resist drugs that block the epidermal growth factor receiver.
Gene data from large public banks were screened against a set of genes tied to histone marks, and TLE1 stood out. Survival checks, pathway scoring, and immune-cell estimates were run, and lab tests that silenced TLE1 probed its role in resistance. Clinicians get a named candidate for predicting who may stop responding and who may gain from immune treatment.
Catalog record
| CREATOR | Na Chen, Tianlin Wang, Yi Li, Ruixia Zhang, Xiduan Wei, Zhenglu Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |